Every 8-K that Perspective Therapeutics, Inc. (CATX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CATX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CATX filings page.
Perspective Therapeutics, Inc. (CATX) reported that it updated its corporate presentation, which has been furnished as an exhibit. The presentation outlines a strategy focused on next‑generation radiopharmaceutical therapy in targeted oncology built around lead‑212 (²¹²Pb) payloads.
The company highlights three independent clinical‑stage programs targeting distinct receptors or antigens: VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma via MC1R, and PSV359 for FAP-ɑ–expressing solid tumors, along with a CCK2R program. The materials describe an estimated $45 billion+ combined solid tumor addressable market for programs VMT-α-NET, VMT01, PSV359, and PSV594, ongoing Phase 1/2a trials, clinical data expected in 2026 including ASCO 2026 analyses, and an integrated platform covering isotope production, regional manufacturing, and intellectual property across the radiopharmaceutical value chain.
Perspective Therapeutics, Inc. reported second quarter 2026 results and provided a broad pipeline and manufacturing update. The company is advancing bamzireotide navoxetan (VMT-α-NET) toward a planned Phase 3 study in SSTR2-positive neuroendocrine tumors, targeting clinical site activation around year-end 2026, subject to regulatory feedback and protocol finalization. VMT01 in MC1R-positive melanoma and PSV359 in FAP-α-positive solid tumors continue in Phase 1/2a development, while PSV594 remains in pre-IND work. An updated VMT-α-NET data set will be presented at ESMO on October 23, 2026.
The company is expanding its 212Pb-based radiopharmaceutical manufacturing network, expecting its Chicago metro site to complete construction in early 2027 and its Los Angeles metro site in the second half of 2027, for four regional sites by year-end 2027. Cash, cash equivalents, and short-term investments totaled $237 million as of June 30, 2026, up from $145 million at December 31, 2025, and are expected to fund planned clinical milestones and operational investments into late 2027.
For the quarter ended June 30, 2026, research and development expenses were $21.5 million versus $16.6 million a year earlier, and general and administrative expenses were $7.8 million versus $7.7 million. Net loss was $26.8 million, or $0.22 per share, compared with a net loss of $21.5 million, or $0.29 per share, in the prior-year quarter. Total assets were $392.0 million and stockholders’ equity was $323.9 million as of June 30, 2026. The company also appointed Paul Lyne, Ph.D. as Chief Science Officer.
Perspective Therapeutics, Inc. provides an updated corporate presentation describing a strategy to “redefine oncology treatment” with next‑generation radiopharmaceuticals built around the alpha‑emitting isotope 212Pb. The company emphasizes engineering the “alpha advantage,” careful isotope selection, and a theranostic approach to treating solid tumors.
The presentation outlines a direct‑to‑hospital delivery model supported by integrated isotope production and daily regional manufacturing of ready‑to‑administer products. Lead programs include VMT‑α‑NET for SSTR2+ neuroendocrine tumors, VMT01 targeting MC1R for melanoma, and PSV359 targeting FAP‑ɑ in advanced solid tumors, all in ongoing Phase 1/2a studies.
Slides reference deepening responses over time and durable disease control for VMT‑α‑NET, preliminary anti‑tumor activity and tolerability for VMT01, improved tumor retention for PSV359, and a broad intellectual‑property portfolio across the radiopharmaceutical value chain, supported by experienced leadership in radiopharmaceutical and drug development.
Perspective Therapeutics, Inc. filed an 8-K to note that it updated its corporate presentation on July 1, 2026. The new presentation highlights its focus on next-generation radiopharmaceuticals for oncology, centered on 212Pb-based therapies and an integrated production and delivery model.
The materials describe a diverse pipeline targeting solid tumors, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α–expressing solid tumors, all in ongoing phase 1/2a trials. The deck also emphasizes a theranostic approach, regional manufacturing, and direct-to-hospital delivery to support ready-to-administer products.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on June 1, 2026 and furnished it as Exhibit 99.1. The presentation highlights a strategy focused on next-generation radiopharmaceuticals using the 212Pb isotope to treat solid tumors through a theranostic approach and integrated isotope production.
The deck describes regional daily production and direct-to-hospital delivery, along with a wholly owned 212Pb-based oncology portfolio. Key programs include VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-ɑ in solid tumors, all in ongoing Phase 1/2a or early clinical trials, with references to safety, exposure, and preliminary anti-tumor activity.
Perspective Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 114,017,755 common shares entitled to vote, 97,882,462 shares were represented, an 85.85% quorum. Stockholders elected six directors to serve until the 2027 annual meeting.
They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. In an advisory vote on the frequency of say-on-pay, a one-year interval received the most support, and the company intends to hold annual advisory votes on executive compensation.
Perspective Therapeutics reported interim clinical results that will be highlighted at the 2026 ASCO meeting for all three of its 212Pb radiopharmaceutical programs. Updated data for [212Pb]VMT-α-NET in neuroendocrine tumors show a safety profile without dose-limiting toxicities or serious renal complications across 64 treated patients, and investigator-assessed responses in multiple cohorts with continued deepening of tumor shrinkage over time.
In metastatic melanoma, the [212Pb]VMT01 3.0 mCi monotherapy cohort showed two confirmed responders among seven heavily pre-treated patients, with six experiencing stable disease or partial response and no dose-limiting toxicities or Grade 4–5 events. For [212Pb]PSV359 in FAP-positive solid tumors, treatment has advanced to Cohort 3 at 6.0 mCi, with earlier cohorts showing only Grade 1–2 adverse events and no dose-limiting toxicities. Overall, the company emphasizes that all three programs remain well-tolerated and plans further data updates in late 2026.
Perspective Therapeutics reported first-quarter 2026 results and highlighted progress across its 212Pb radiopharmaceutical pipeline. Cash, cash equivalents and short-term investments were about $271 million as of March 31, 2026, up from $145 million at year-end 2025, helped by a February underwritten offering that generated roughly $164 million in net proceeds. Management believes this cash should fund current clinical milestones and operations into late 2027.
Research and development expenses rose to $21.4 million from $14.3 million a year earlier as the company expanded staff and clinical and manufacturing activities. General and administrative costs declined to $7.0 million from $7.8 million. Net loss widened to $26.2 million, or $0.25 per share, compared with a loss of $18.2 million, or $0.25 per share, in 2025.
The company reported three clinical-stage programs in neuroendocrine tumors, melanoma and FAP-positive solid tumors, with multiple data and follow-up milestones expected in 2026. It is also expanding a regional manufacturing network, including a flagship Chicago facility planned to complete construction in 2026.
Perspective Therapeutics, Inc. posted an analyst presentation to its website that includes preliminary, estimated financial information and extensive updates on its clinical and manufacturing strategy in targeted oncology. The slides cover its 212Pb-based theranostic programs, including VMT-α-NET for SSTR2+ neuroendocrine tumors and meningioma, along with early data, case studies and treatment landscape context. The presentation also highlights the company’s integrated isotope production, regional manufacturing model and direct-to-hospital delivery aimed at supporting daily production and broad market reach. All financial estimates, including estimated cash, cash equivalents and short-term investments as of March 31, 2026, are unaudited and subject to change after completion of quarter-end procedures.
Perspective Therapeutics reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with advanced SSTR2-positive neuroendocrine tumors. As of the March 4, 2026 data cut-off, 64 patients had received at least one treatment across three dose cohorts.
The company highlighted a favorable safety profile with no dose-limiting toxicities, no Grade 4 or 5 adverse events, no treatment-related discontinuations, and no serious renal complications or clinically significant treatment-related myelosuppression. Grade 3 or higher treatment-emergent adverse events occurred in 23 patients, and one previously reported Grade 4 lymphopenia was revised to Grade 3.
Among two patients in Cohort 1 and 23 in Cohort 2, 18 of 25 patients (72%) were alive without progression, and 10 of 23 Cohort 2 patients (43%) had objective responses by investigator-assessed RECIST v1.1, with several showing deepening responses over time. Perspective plans further data updates in 2026 and continued regulatory engagement.
Perspective Therapeutics filed a Form 8-K to note that it has updated its corporate presentation, which is attached as Exhibit 99.1. The presentation highlights its focus on next-generation radiopharmaceuticals built on a proprietary lead-212 (212Pb) radioligand platform designed to optimize the therapeutic index and targeted tumor delivery.
The company outlines a wholly owned 212Pb-based oncology portfolio, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 targeting FAP-α in solid tumors. Early Phase 1/2a trials are described as showing anti-tumor activity and favorable tolerability, with Phase 1/2 data expected across all three programs in 2026.
Perspective Therapeutics reported a larger net loss for 2025 while advancing its radiopharmaceutical pipeline and strengthening its balance sheet. Net loss was $103.1 million, or $1.40 per share, compared with $79.3 million, or $1.23 per share in 2024, driven mainly by higher research and development spending.
Research and development expenses rose to $84.2 million, up about 102%, as the company expanded clinical activities for its VMT-α-NET, VMT01 and PSV359 programs and recorded a $10.0 million non-cash impairment on a deprioritized preclinical asset. General and administrative expenses increased to $30.2 million from $26.6 million.
Cash, cash equivalents and short-term investments were about $145 million as of December 31, 2025, down from $227 million a year earlier. In February 2026, the company closed an underwritten equity offering with net proceeds of approximately $164 million, and now expects its cash resources to fund planned clinical milestones and operations into late 2027.
Perspective Therapeutics, Inc. completed an underwritten equity offering, selling 39,576,088 shares of common stock and issuing pre-funded warrants to purchase 6,598,046 shares, raising approximately $175 million in gross proceeds.
The shares were priced at $3.79 each, and the pre-funded warrants at $3.789 each, reflecting a $0.001 exercise price. The company plans to use net proceeds to advance clinical development of its product candidates, invest in manufacturing facilities, and for working capital and other general corporate purposes, with potential additional use for future acquisitions or licensing opportunities.
Perspective Therapeutics, Inc. filed an 8-K to note that it has updated its corporate presentation and posted it on its website. The presentation includes preliminary estimated and projected financial information, including estimated cash, cash equivalents and short-term investments as of December 31, 2025.
The company emphasizes that these figures are unaudited and have not been reviewed or compiled by its independent registered public accounting firm, WithumSmith+Brown, PC, which provides no assurance on the data. Actual results for the year ended December 31, 2025 may differ once closing procedures and final adjustments are completed.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on January 14, 2026. The company is a Delaware corporation whose common stock trades on the NYSE American under the symbol CATX.
The updated corporate presentation is included as Exhibit 99.1 and is incorporated by reference into the Item 8.01 Other Events section. No new financial statements or major transactions are described in this excerpt, which focuses on making the refreshed investor materials publicly available.
Perspective Therapeutics, Inc. filed a current report to let investors know it has issued a new press release describing business updates and strategic priorities. The company states that the press release, dated January 12, 2026, is attached as an exhibit and incorporated by reference, meaning the detailed operational and strategic information is contained in that accompanying document rather than in the body of this report.
Perspective Therapeutics, Inc. reported that it issued a press release on January 9, 2026 sharing updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET. This study involves patients with unresectable or metastatic neuroendocrine tumors that express somatostatin receptor subtype 2, a specific tumor marker. The updated data are being presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held January 8–10, 2026 in San Francisco. Detailed clinical results are contained in the related press release, which is attached as an exhibit.
Perspective Therapeutics, Inc. reported that it updated its corporate presentation on December 1, 2025. The new version is being made available to the market as an exhibit to a current report, giving investors and other stakeholders refreshed information about the company’s business and strategy. The company’s common stock continues to trade on the NYSE American under the symbol CATX.
Perspective Therapeutics (CATX) furnished a press release announcing its financial results for the quarter ended September 30, 2025, and provided recent business highlights. The company also posted an updated corporate presentation on its website.
The press release was furnished as Exhibit 99.1 under Item 2.02, and the corporate presentation was filed as Exhibit 99.2 under Item 8.01. The Item 2.02 information is expressly not deemed “filed” under Section 18 of the Exchange Act.
Perspective Therapeutics, Inc. (CATX) reported an administrative update: the company updated its corporate presentation. The presentation was furnished under Item 8.01 and attached as Exhibit 99.1, dated November 6, 2025.
Perspective Therapeutics (CATX) amended and restated employment agreements for its CEO Johan (Thijs) Spoor, Chief Accounting Officer Jonathan Hunt, and Chief Medical Officer Dr. Markus Puhlmann. The updates reflect current base salaries and revise change-in-control provisions.
Base salaries are $680,000 for Mr. Spoor, $451,500 for Mr. Hunt, and $516,700 for Dr. Puhlmann. If employment ends without cause or for good reason during the three months before or 12 months after a change in control, severance includes salary continuation for 12 months (18 months for Mr. Spoor), a pro‑rated target bonus, an additional amount equal to the target bonus (1.5x target for Mr. Spoor), and COBRA premiums for up to 12 months (18 months for Mr. Spoor).
Equity awards subject to time-based vesting accelerate to full vesting, and performance-based awards vest at target upon qualifying terminations in the protection period or if awards are not assumed, replaced, or continued at closing, subject to a release of claims. Other existing terms remain in effect.
Perspective Therapeutics (CATX) filed an 8‑K announcing a press release and presentation with updated interim results from its Phase 1/2a study of [212Pb]VMT‑α‑NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors. The data are being presented at ESMO 2025 in Berlin. The materials also include the Company’s estimated cash, cash equivalents and short‑term investments as of September 30, 2025, which are preliminary, unaudited, and subject to change.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation. The updated presentation, dated October 1, 2025, is furnished as Exhibit 99.1 to the report and incorporated by reference into the other events section.
Perspective Therapeutics, Inc. appointed Joel Sendek as its new Chief Financial Officer and principal financial officer, effective September 4, 2025, replacing Juan Graham in the CFO role. The company detailed Mr. Sendek’s background, compensation, equity incentives, and severance protections in his employment agreement.
Mr. Sendek will receive a $500,000 annual base salary, a target annual bonus equal to 40% of base salary, and a one-time option grant to purchase 600,000 shares of common stock, vesting over four years. The agreement also provides 12 months of salary, bonus-related amounts, COBRA premiums, and accelerated vesting of equity awards under certain termination and change-in-control conditions, subject to a release of claims.
Perspective Therapeutics, Inc. reported that its Board of Directors voted to increase the board size from five to six members and appointed Maya Martinez-Davis as a director, effective September 3, 2025. She will also serve on the Compensation Committee and the Nominations and Corporate Governance Committee.
Under the company’s Non-Employee Director Compensation Program, Ms. Martinez-Davis will receive an annual cash retainer of $60,000 and an initial grant of 75,000 stock options, with the grant date fair value capped at $450,000. These options vest in 36 equal monthly installments starting one month after the grant date, contingent on her continued service. The company expects her to enter into its standard indemnification agreement, and it states there are no related-party transactions requiring disclosure. A press release announcing her appointment was issued on September 3, 2025 and furnished as Exhibit 99.1.
Perspective Therapeutics, Inc. filed a current report to note that on September 2, 2025, the company updated its corporate presentation. The updated presentation is included as Exhibit 99.1 and is incorporated by reference into the disclosure. This type of presentation typically provides an overview of the business and strategy for investors, but the specific contents are not detailed here.
Perspective Therapeutics, Inc. reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and furnished that press release as Exhibit 99.1 to this Form 8-K. The filing also states the company posted an updated corporate presentation on its website and furnished that presentation as Exhibit 99.2. The 8-K clarifies that the information is "furnished" and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act.
The filing text does not include the actual financial figures or metrics; those details are contained in the referenced exhibits. This disclosure informs investors that quarter-end results and investor materials have been released, while the legal notice about furnishing limits incorporation and Section 18 liability.
Perspective Therapeutics (NYSE: CATX) announced significant developments in its clinical trials program on June 21, 2025. The company has received FDA alignment to open the third dosing cohort of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET, targeting patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies.
Additionally, the company presented findings from a dosimetry sub-study using [202Pb]VMT-α-NET as an imaging agent at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting in New Orleans. This presentation demonstrates the company's progress in developing innovative imaging solutions for neuroendocrine tumor treatment.
The 8-K filing also notes that Perspective Therapeutics has updated its corporate presentation on June 23, 2025, suggesting potential strategic or operational updates to its business model and development pipeline.